Lukas Biomedical (ROCO:6814) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
63 GF Score
Price NT$22.30
GF Value NT$21.01
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Lukas Biomedical 5-Year Yield-on-Cost %?

Lukas Biomedical ROCO:6814 +3.72% 63 5-Year Yield-on-Cost % is 0.00 as of Aug. 22, 2026. GuruFocus rates ROCO:6814 with a GF Score™ of 63/100 and a GF Value™ of NT$21.01 (Fairly Valued). The stock has 8 warning signs investors should review. Among 150 Biotechnology companies, Lukas Biomedical ranks worse than 666666% on this metric.

Lukas Biomedical's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Lukas Biomedical's 5-Year Yield-on-Cost % or its related term are showing as below:



ROCO:6814's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.655
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Lukas Biomedical  (ROCO:6814) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Lukas Biomedical 5-Year Yield-on-Cost % Related Terms


ROCO:6814 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Lukas Biomedical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lukas Biomedical 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's 5-Year Yield-on-Cost % falls into.


ROCO:6814
63GF Score
Lukas Biomedical Inc ROCO:6814
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Lukas Biomedical is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Lukas Biomedical (ROCO:6814) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lukas Biomedical and its competitors. According to the industry distribution chart, Lukas Biomedical ranks #999999 out of 150 companies in the Biotechnology industry.
Is Lukas Biomedical's 5-Year Yield-on-Cost % too high?
Lukas Biomedical's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Lukas Biomedical ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lukas Biomedical has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Lukas Biomedical in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Fairly Valued. The stock's GF Value™ is NT$21.01, compared to a current price of NT$22.30 — trading 6.1% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Lukas Biomedical's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$22.30 is trading 6.1% above its estimated GF Value™ of NT$21.01. GuruFocus considers Lukas Biomedical to be Fairly Valued.

Key valuation signals for ROCO:6814:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: NT$21.01 vs. price of NT$22.30 (6.1% above fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
63GF Score

Get the complete analysis for ROCO:6814

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.30
Price
NT$21.01
GF Value